Progress of targeted and immune therapies in primary central nervous system lymphoma
10.3760/cma.j.cn115355-20230508-00234
- VernacularTitle:靶向及免疫治疗在原发性中枢神经系统淋巴瘤中的研究进展
- Author:
Qian MI
1
;
Jianxia HE
Author Information
1. 山西医科大学第五临床医学院，太原 030012
- Keywords:
Lymphoma;
Central nervous system neoplasms;
Molecular targeted therapy;
Chimeric antigen receptor T-cell;
Immune checkpoint inhibitors
- From:
Cancer Research and Clinic
2024;36(9):717-720
- CountryChina
- Language:Chinese
-
Abstract:
Primary central nervous system lymphoma (PCNSL) is a rare highly aggressive brain tumor originating from the extranodal sites, with a low 5-year overall survival rate. Some patients may have drug resistance or relapse, the therapeutic regimens based on high-dose methotrexate is insufficient to meet the clinical treatment needs. With the in-depth study of characteristics of lymphoma-related genes and immune microenvironment, new pathways continue to emerge, including Bruton tyrosine kinase inhibitors, immune preparations such as lenalidomide, anti-programmed death receptor-1 antibodies, chimeric antigen receptor T-cell therapy, etc. This review focuses on the progress of targeted drugs and immunotherapy for PCSNL.
